

Filippo Pietrantonio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6477687/filippo-pietrantonio-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194
papers

4,693
citations

36
h-index

59
g-index

209
ext. papers

6,372
ext. citations

6.2
avg, IF

5.25
L-index

#	Paper	IF	Citations
194	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , 2022 , 27, e29-e36	5.7	0
193	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10,		2
192	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
191	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102453	2.2	2
190	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100472	3.6	0
189	BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 103647	7	0
188	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. <i>European Journal of Cancer</i> , 2022 , 167, 23-31	7.5	0
187	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. <i>JCO Precision Oncology</i> , 2022 , 6, e2200015	3.6	2
186	Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.. <i>JCO Precision Oncology</i> , 2022 , 6, e2200037	3.6	0
185	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. <i>European Journal of Cancer</i> , 2021 , 161, 90-98	7.5	3
184	Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021 , 13,	6.6	2
183	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. <i>Tumori</i> , 2021 , 107, 353-359	1.7	2
182	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	4
181	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021 , 24, 897-912	7.6	1
180	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83	7.5	8
179	Microsatellite instability in Gastric Cancer: Between lights and shadows. <i>Cancer Treatment Reviews</i> , 2021 , 95, 102175	14.4	17
178	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1561-1569	9.7	3

177	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		5
176	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021 , 28, 2778-2796	12.7	13
175	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021 , 1, 311-325		
174	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021 , 13,	6.6	7
173	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 150, 155-167	7.5	15
172	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021 , 107, 150-159	1.7	2
171	The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 4-10	3.6	5
170	Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3332-3342	3.1	5
169	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021 , 26, 302-309	5.7	4
168	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 144, 31-40	7.5	5
167	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021 , 29, 3971-3980	3.9	3
166	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021 , 27, 3126-3140	12.9	6
165	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2505-2514	12.9	3
164	Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. <i>ESMO Open</i> , 2021 , 6, 100036	6	25
163	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
162	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , 2021 , 7, 1529-1535	13.4	13
161	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		2
160	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 153, 16-26	7.5	1

159	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
158	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020 , 25, 803-809	5.7	17
157	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020 , 123, 403-409	8.7	22
156	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020 , 78, 195-206	10.2	67
155	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020 , 135, 78-88	7.5	5
154	KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 219-225	3.8	16
153	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 497-507	21.7	98
152	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 685-698	5.1	2
151	MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response. <i>Clinical Cancer Research</i> , 2020 , 26, 3495	12.9	0
150	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020 , 135, 230-239	7.5	6
149	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020 , 25, e460-e468	5.7	13
148	Caring for Patients With Cancer During the COVID-19 Outbreak in Italy. <i>JAMA Oncology</i> , 2020 , 6, 821-822	3.4	20
147	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 783-794	3	5
146	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1017-1024	12.9	8
145	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 156-164	3.8	12
144	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020 , 26, 919-931	50.5	55
143	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020 , 82, 101935	14.4	7
142	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	3

141	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020 , 139, 81-89	7.5	3
140	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 138, 1-10	7.5	9
139	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020 , 20, 683	4.8	26
138	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020 , 9,	7.9	7
137	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020 , 147, 2303-2315	7.5	7
136	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 191-199.e6	3.8	10
135	Gastric cancer: Translating novels concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019 , 79, 101889	14.4	39
134	CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599	8.7	14
133	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3110	2.2	35
132	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3392-3400	2.2	123
131	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019 , 9, 12993	4.9	11
130	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019 , 79, 5884-5896	10.1	26
129	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 465-472	3.5	11
128	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019 , 97, 38-43	3.6	14
127	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2858	4.9	26
126	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019 , 9, 3545	4.9	18
125	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 116-124	3.8	5
124	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e179-e190	3.8	7

123	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019 , 25, 3954-3961	12.9	36
122	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489	6	8
121	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019 , 19, 283	4.8	8
120	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 556-563	3.5	20
119	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 125-132.e2	3.8	23
118	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-14	3.6	6
117	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the BRAF BeCoolR study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130	7.5	29
116	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
115	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 66-66	2.2	15
114	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019 , 4, e000496	6.4	0
113	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
112	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-11	3.6	
111	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019 , 107, 164-174	7.5	6
110	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 34-43.e6	3.8	5
109	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 343-350	13.4	134
108	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019 , 145, 576-585	7.5	10
107	Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 259-277	3.8	3
106	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018 , 25, 878-884	3.1	13

105	Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series. <i>Annals of Surgical Oncology</i> , 2018 , 25, 878-884	3.1	36
104	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018 , 13, 227-234	5	23
103	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018 , 118, 955-965	8.7	10
102	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018 , 29, 1394-1401	10.3	47
101	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , 2018 , 19, 1047-1068	2.6	9
100	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000403	6	15
99	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	17
98	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98	4.8	6
97	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018 , 95, 344-352	3.6	9
96	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018 , 29, 1800-1806	10.3	22
95	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , 2018 , 9, 2287	17.4	14
94	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3505-3505	2.2	20
93	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018 , 24, 1082-1089	12.9	58
92	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018 , 3, e000389	6	3
91	Glomerular filtration rate: A prognostic marker in atrial fibrillation-A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. <i>Clinical Cardiology</i> , 2018 , 41, 1570-1577	3.3	5
90	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. <i>Cell Metabolism</i> , 2018 , 28, 848-865.e6	24.6	107
89	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018 , 23, 1178-1187	5.7	31
88	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017 , 17, 221-226	3.5	6

87	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	126
86	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017 , 71, 43-50	7.5	22
85	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
84	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017 , 73, 74-84	7.5	32
83	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017 , 13, 2265-2275	3.6	8
82	Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017 , 86, 197-206	7.5	16
81	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017 , 28, 3009-3014	10.3	48
80	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 148-163	2.8	54
79	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. <i>Oncology</i> , 2017 , 93, 279-286	3.6	8
78	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
77	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6
76	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017 , 552, 116-120	50.4	290
75	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 347-352	8.7	22
74	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
73	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2414-2422	12.9	111
72	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
71	Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2017 , 24, 167-175	3.1	26
70	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e191-e198	3.8	9

69	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017 , 8, 16887-16898	3.3	24
68	Identification and characterization of a novel rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , 2017 , 8, 55353-55360	3.3	23
67	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845	5.2	9
66	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 24-8	7	16
65	Osteopontin, E-cadherin, and E-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 412-420	7.6	25
64	Toward the molecular dissection of peritoneal pseudomyxoma. <i>Annals of Oncology</i> , 2016 , 27, 2097-2103	10.3	45
63	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
62	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016 , 6, 1315-1323	10.7	
61	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 963-71	24.4	71
60	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016 , 14, 125	8.5	26
59	Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 209-22	7	68
58	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 99-106	7	11
57	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 337-43	5	18
56	Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. <i>Reviews on Recent Clinical Trials</i> , 2016 , 11, 56-62	1.2	9
55	How the lab is changing our view of colorectal cancer. <i>Tumori</i> , 2016 , 102, 541-547	1.7	9
54	Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer. <i>Tumori</i> , 2016 , 102, e15-9	1.7	10
53	Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study. <i>Annals of Surgical Oncology</i> , 2016 , 23, 4222-4230	3.1	19
52	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016 , 7, 13665	17.4	121

51	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016 , 139, 2859-2864	7.5	57
50	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015 , 137, 1467-74	7.5	25
49	In reply. <i>Oncologist</i> , 2015 , 20, e5	5.7	1
48	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015 , 51, 473-481	7.5	12
47	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 8884-95	6.3	13
46	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 272-81	7	13
45	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
44	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1994-1999	10.3	93
43	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 800-7	7.5	40
42	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 581-8	3.8	41
41	BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015 , 113, 1634-5	8.7	10
40	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015 , 20, 1261-5	5.7	29
39	Reply to the letter to the editor New life for retrospective study in the precision oncology era By Orlandi et al. <i>Annals of Oncology</i> , 2015 , 26, 2353	10.3	
38	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
37	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015 , 10, 127-33	4	1
36	LightSNiP assay is a good strategy for pharmacogenetics test. <i>Frontiers in Pharmacology</i> , 2015 , 6, 114	5.6	3
35	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66	7	50
34	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015 , 32, 182	3.7	18

33	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015 , 16, 2069-81	2.6	13
32	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 587-94	7.5	329
31	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014 , 25, 404-8	10.3	51
30	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , 2014 , 11, 259-262	2.2	4
29	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , 2014 , 9, e92147	3.7	17
28	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. <i>Cancers</i> , 2014 , 6, 1753-68	6.6	13
27	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , 2014 , 19, 845-50	5.7	37
26	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , 2014 , 86, 289-94	3.6	8
25	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology, The</i> , 2014 , 15, e581	21.7	1
24	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1228-37	3.8	32
23	Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 545-9	2.7	8
22	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. <i>PLoS ONE</i> , 2014 , 9, e108940	3.7	46
21	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014 , 9, 155-62	5	23
20	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014 , 2, 835-9	1.6	21
19	MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3982-90	3.3	36
18	Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4516-25	5.6	23
17	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013 , 30, 610	3.7	7
16	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013 , 15, 582-6	3.6	2

15	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. <i>Oncology</i> , 2013 , 84, 191-9	3.6	27
14	Role of cMET in the development and progression of colorectal cancer. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 18056-77	6.3	38
13	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1098-103	4.6	22
12	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , 2013 , 33, 1257-66	2.3	48
11	Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. <i>Oncologist</i> , 2012 , 17, 1426-8	5.7	10
10	Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. <i>Translational Oncology</i> , 2012 , 5, 155-9	4.9	13
9	Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab. <i>Medical Oncology</i> , 2012 , 29, 2838-41	3.7	3
8	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , 2012 , 23, 2771-2772	10.3	1
7	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012 , 98, 267-9	1.7	1
6	Management of advanced genitourinary tumors. <i>Tumori</i> , 2012 , 98, 264-6	1.7	
5	Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. <i>Drugs and Aging</i> , 2011 , 28, 83-91	4.7	1
4	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2011 , 6, 181-6	5	7
3	Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report. <i>Tumori</i> , 2010 , 96, 154-156	1.7	7
2	An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review. <i>Tumori</i> , 2010 , 96, 1031-1034	1.7	1
1	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009 , 3, 79-87	4.3	3